Syringa species

Plants belonging to the family Oleaceae, which consists of 27 genera and 400 species worldwide, have important applications in the daily life of people living in developing countries. Plants of many well-known genera, including Forsythia, Syringa, and Osmanthus, have been widely used for medicinal and industrial purposes. For instance, the stems and roots of S. pinnatifolia var. alashanensis is the major composition of atraditional formula ‘Ba wei chenxiang’ powder that is used for treatment of asthma, cardiopalmus, and angina [1].

Most Syringa plants are deciduous shrubs and arbors and include more than 40 species distributed around Europe and Asia [2]. At present, 22 species are found in China, of which 18 are endemic species that are mainly distributed in the southwestern part of Sichuan, Yunnan, Tibet, and other Northwestern regions. Many Syringa species, such as S. chinensis, S. meyeri, and S. pekinensis, are used for making ornaments. Flowers of S. oblata and S. reticulata var. mandshurica are an ideal source of aroma oils or nectar. Some Syringa plants are also used for construction purposes or for manufacturing furniture [1].

Previous phytochemical studies on Syringa species have revealed the presence of more than 140 secondary metabolites, including iridoids, lignans, phenylethanoids, their glycosides, minor organic acids, and essential oils [3,4]. Modern pharmacological studies have shown the bioactivities of these metabolites, such as antitumor, antihypertensive, anti-oxidant, anti-inflammatory activities, and so on [5]. However, a systematic review of these studies has not been performed to date. This review summarizes the phytochemical and pharmacological progress on Syringa to date by focusing on its chemical classification, structural features, and biological and pharmacological applications to provide information for further research on this genus

Iridoids are one of the most important natural compounds that are widely distributed in various plant families such as Plantaginaceae, Rubiaceae, and Scrophulariaceae [6]. Iridoids are extensively present in almost all Syringa species and have antitumor, antihypertensive, anti-inflammatory, anti-oxidant, and antifungal activities. In addition, iridoids play an important role in defense mechanism of ants [7]. Among all the iridoids reported in this genus, secoiridoids are the most abundant and have been shown to have antitumor activity. To date, 46 iridoids (1–46) have been described, including secoiridoids (1–30 and 40–44), eight typical iridoids (32–39), and three minor dimers (31, 45, and 46). Most iridoids exist as glycosides and are mainly produced by the glycosylation of glucose and galactose. Syringa iridoids are generally substituted by various acid fragments and phenolic moieties such as 1-O-cinnamoyl-β-d-glucopyranosyl, p-hydroxphenethyl, 3, 4-dihydroxy-phenethyl, and caffeic acid, which contribute to their low polarity. Syringa iridoids have antitumor (33 and 40) [8,9], antihypertensive (4), and anti-oxidant (4 and 31) activities [10].

Lignans are another major compounds in this genus, particularly in S. komarowii [27], S. pubescens [3], S. reticulata [10], S. velutina [28], S. patula [5], S. vulgaris [29], S. pinnatifolia var. alashanensis [30,31], and S. reticulata var. mandshurica [32]. Syringa species have 34 lignans and their glycosides (47–80), including monoepoxylignans (47–60, 62) and their dimers (63 and 64), neolignans (61, 73–74), cyclolignans (65 and 66), simple lignans (67–72), and bisepoxylignans (75–80). Lignans also exhibit many bioactivities. For example, compound 50 has anti-oxidant activity [10]; compounds 57 and 58 have antifungal activities [32]; and compound 75 has significant cytotoxic, antihypertensive, anti-inflammatory, and anti-oxidant activities [5].

Other compounds
Phenylethanoids (81–105), phenylpropanoids and their analogues (106–121), flavonoids (122–128), sesquiterpenes (129 and 130), and other minor compounds have been described in Syringa plants. Of these, phenylethanoids are predominant, particularly in S. reticulata [10,12,35], S. vulgaris [29], S. pubescens [3], S. oblata var. alba [36], S. reticulata var. mandshurica [35], S. afghanica [13], and S. komarowii [27]. Sesquiterpenes (129 and 130) are present in the stems of S. pinnatifolia var. alashanensis [37]. These miscellaneous compounds have cytotoxic, anti-inflammatory, antihypertensive, anti-oxidant, and antifungal properties.

Besides the abovementioned compounds, Syringa plants contain essential oils that form the most important constituents not only because of their economic utility but also because of their potential medicinal value as antimicrobial, antipyretic, and antiviral agents. Multiple analytical techniques such as headspace solid-phase microextraction, gas chromatography–mass spectrometry (GC–MS), GC–MS coupled with heuristic evolving latent projections, moving subwindow searching, nuclear magnetic resonance spectroscopy, and X-ray single-crystal diffraction analysis have been used to identify essential oils from fresh flowers of S. oblata var. alba. For instance, 39 volatile oil constituents were identified, including four characteristic isomers of lilac alcohols (lilac alcohols A–D) and lilac aldehydes A–D [38]. Ninety-five components, including 15 terpenes, 14 oxygenated terpenes, 10 aromatic compounds, and 13 n-alkanes were quantitatively analyzed from S. oblata buds [39]. Forty-nine components were described from essential oil of S. pubescens flowers, most of which are monoterpenes and sesquiterpenes [40]. Thirty-four volatile oil components, accounting for around 64.7% (zerumbone) of the toil oil, were identified from roots and barks of S. pinnatifolia var. alashanensis [4]. These data imply that Syringa plants could be considerably different from each other in terms of their essential oil components.

Pharmacological activities
Various crude extracts and isolated compounds from Syringa plants have shown significant antitumor, antihypertensive, anti-inflammatory, anti-oxidant, and antifungal activities.

Antitumor activity
Cytotoxic activities of crude extracts and chemicals obtained from Syringa plants have been extensively evaluated against various tumor cell lines. Aqueous extracts from the flowers and leaves of S. pubescens inhibited the growth of L2215 (hepatitis B virus) cells, with a 50% inhibitory concentration (IC50) value of 78 μg/mL [51]. Hydrolysis of isoligustroside (1) and isooleuropein (2) were assayed using a disease-oriented panel of 39 human cancer cell lines. The results showed that the hydrolysis product of compound 2 had moderate cytotoxic activity against lung cancer cell lines DMS273 [log GI50 = 5.19 (6.4 μM)] and DMS114 [log GI50 = 5.06 (8.7 μM)]. Preliminary analysis of structure–activity relationship suggested that C-5′-OH plays an important role in this cytotoxic activity [11]. Isooleoacteoside (40) showed weak cytotoxicity against LOX-IMVI melanoma cell line, with GI50 value of 16 μM, and syringopicroside B (33) showed weak cytotoxic activity against NCI-H522 lung cancer cell line, with GI50 value of 13 μM [9]. MTT assay used to assess the cytotoxicities of syringaresinol (78) and oleoside 11-methyl ester (3) showed that compound 78 had a strong dose-dependent effect on HepG2 cell line, with an IC50 value of 94.6 μM, and compound 3 has a dose–response curve of low slope, with a high IC50 value of 186.5 μM, compared with positive controls dexamethasone (IC50 14.2 μM) and paclitaxel (IC50 700 nM). However, compound 78 was cytotoxic even at the lowest concentration of 29.9 μM. β-Amyrin acetate (139) showed weak cytotoxicity against A2780 human ovarian cancer and HepG2 cell lines [5]. Oleuropein (4) and 2-(3, 4-dihydroxy)-phenylethyl-β-d-glucopyranoside (83) showed evident cytotoxicities against P-388, L-1210, SNU-5, and HL-60 cell lines, with IC50 values varying from 8.5 to 139.8 μM [12]. Verbascoside (86) showed moderate cytotoxic activity against SNB-75 (brain cancer) and SNB-78 cell lines, with GI50 values of 7.4 and 7.7 μM, respectively [9]. A pharmacokinetic study showed that compound 86 interacted with the catalytic domain of PKC and acted as a competitive inhibitor of adenosine triphosphate (Ki = 22 μM) and non-competitive inhibitor of phosphate acceptor (histone III). Because 83 is one part of 86 in its molecular structure, the cytotoxic effect could be attributed to 3, 4-dihydroxyphenylethoxy moiety, which may act as a competitive inhibitor to the catalytic domain of PKC. Therefore, 83 is a potentially essential skeleton of most cytotoxic phenylethanoid glycosides [12].

Hypotensive activity
Syringin (110) and kaempferol-3-O-rutinoside (125) showed antihypertensive activity. Intravenous injection of 10 mg/kg of compound 86 significantly decreased systolic, diastolic, and mean arterial blood pressure in Pentothal-anesthetized rats. Moreover, the depressor effect of compound 86 was independent of muscarinic and histaminergic receptors because it did not block the effect of atropine (an antimuscarinic agent) and chlorpheniramine/cimetidine (antihistaminergic agents) [36]. In vitro studies showed that oleuropein (4) significantly lowered blood pressure. It is interesting to note that antihypertensive effect of compound 4 (33% at 30 mg/kg dose) on the blood pressure of anesthetized rats was similar to that of compound 86 (39.04% ± 2.38% at 10 mg/kg dose) [14,36], which is probably because of the similarity in their structures, with both possessing the same aromatic fragment having two hydroxy groups.

Anti-inflammatory activity
Iridoid glycosides (IGs) exerted obvious anti-inflammatory effects on ulcerative colitis in vivo by inhibiting relative proinflammatory cytokines [53]. IGs significantly ameliorated macroscopic damages and histological changes, reduced the activity of myeloperoxidase, and strongly inhibited epithelial cell apoptosis. Moreover, IGs markedly decreased the levels of tumor necrosis factor-α, interleukin-8, cyclooxygenase-2, and transforming growth factor-β1 in colonic tissues in a dose-dependent manner. Moreover, effects of IGs (160 and 240 mg/kg) were superior to those of positive control salicylazosulfapyridine (150 mg/kg). Furthermore, IGs significantly blocked NF-κB signaling by inhibiting inflammatory bowel phosphorylation/degradation and inhibitor kappa B kinase β activity; downregulated protein and mRNA expressions of Fas/FasL, Bax, and caspase-3; and activated Bcl-2 in intestinal epithelial cells [53,54]. β-Amyrin acetate (139) and syringaresinol (78) at a dose of 20 μg/mL evidently inhibited lipopolysaccharide-induced nitric oxide (NO) production, with inhibition rates of 49.97% and 33.21%, respectively [5].

Liver-protective and cholagogic effects
Crude extract of Syringa species, interferon (IFN), and an injection of “Gan-Yan-Ling” were compared to evaluate their liver-protective effects on the survival rates of HepG2.215 cells and secretion of hepatitis B surface antigen (HBsAg) and HBeAg. The results indicated that all the three assayed drugs may suppress the secretion of HBsAg and HBeAg from HepG2.215 cells in a dose-dependent manner, with the effect of crude extract of Syringa being intermediate those of IFN and Gan-Yan-Ling. Therefore, extracts of Syringa plant could be used to develop effective and less toxic antihepatitis B medicines [55].

Aqueous extracts of S. reticulata var. mandshurica significantly decreased the levels of alanine transaminase and aspartate transaminase and the concentration of malondialdehyde in the serum but increased the activity of superoxide dismutase (SOD) in the liver. These extracts showed protective effects on acute liver injury induced by CCl4 in mice [56]. In addition, the essential oils of Syringa exerted protective effects on the liver and cholecyst [39].

Antifungal activity
Phenylpropanoids such as verbascoside (86) and forsythiaside (82) exhibit significant antimicrobial activity [29]. Compounds 93 and 94 at 1- mM concentration inhibited the radial growth of Phytophthora capsici after 6 days of incubation, with inhibition rates 59.1% and 72.5%, respectively [43]. Two sesquiterpenes, guai-9-en-4β-ol (129) and 4, 15-dinorguai-1, 11-dien-9, 10-dione (130), have antibacterial and antifungal properties. Compound 129 was active against Bacillus coagulans [inhibition zone (IZ) = 15.34 mm] and Aspergillus niger (IZ = 13.20 mm) while compound 130 significantly inhibited Escherichia coli (IZ = 15.34 mm) and Fusarium oxysporum (IZ = 15.32 mm) [37].

Compound 3 showed effective antimicrobial activity against Lactobacillus pentosus (IZ = 1 mm), and compound 139 inhibited the growth of Candida species at concentrations of 30–250 μg/mL [5].

Antioxidant activity
A 70% EtOH extract of S. reticulata barks showed potent superoxide anion and DPPH free radical scavenging activities, with EC50 values of 5.88 and 38.10 μg/mL, respectively [10].

Among the compounds isolated from the bark of S. reticulata, six (4, 31, 50, 77, 83, and 111) showed significant superoxide anion scavenging activity, with EC50 values of 2.57, 4.97, 10.64, 15.98, 4.97, and 14.14 μg/mL, respectively. Compound 4 also interacted with the stable free radical DPPH, with an IC50 value of 40.4 μM [8,10]. These different anti-oxidant activities are closely related to their structural features. Presence of 2-(3, 4-dihydroxyphenyl)-ethoxy moiety might be important for a higher activity because the most potent compounds (EC50 = 2.57–4.97 μM), including the two secoiridoid glycosides (31 and 4) and a phenylethanoid glycoside (83), possess the same structural features. Comparison of the structures of compounds 4 and 83 with those of 8(Z)-ligstroside (21) and salidroside (89) showed that presence of ortho-coupling hydroxyl group at C-2 might be responsible for their different activities. It has been previously reported that 1, 2-dihydroxybenzene moiety is crucial to its DPPH scavenging activity [10].

Syringaresinol (78) showed a strong scavenging activity against DPPH, with EC50 value as low as 12.5 μg/mL, which might be responsible for its strong inhibition of NO production [5].

Eugenol (112) inhibited the catalytic activity of H2O2/Ca2+ human erythrocyte membrane lipid peroxidation at a concentration of 200 μmol/L, with an inhibition rate of 62%, and completely suppressed the catalytic activity of dibenzoyl peroxide/Ca2+ human erythrocyte membrane lipid peroxidation at a concentration of 100 μmol/L. Compound 112 exerted its effect in a non-competitive manner by reacting with Ca2+ and inhibiting the formation of hydroxyl radicals, thus, protecting the cell membrane lipid from oxidation [2].

Inhibition of platelet aggregation
Aqueous extract of S. aramaticum significantly inhibited adenosine diphosphate (ADP) and collagen-induced platelet aggregation, with inhibition rates of 37.4% and 69.7%, respectively [57]. Mandshuricols A (57) and B (58) showed antagonistic activities on platelet-activating factor (PAF) in [3H]PAF receptor binding assay, with IC50 values of 4.8 × 10−5 and 3.5 × 10−5 M, respectively [32].

Essential oils from the stems and roots of S. pinnatifolia var. alashanensis (SPEO) reduced the deviation of ST segment; decreased the levels of lactate dehydrogenase, creatine kinase, and troponin T; and increased the activity of SOD. These protective effects were further confirmed by histopathological examination [58]. Treatment with both 8 and 32 mg/kg SPEO prolonged the survival of mice under hypoxia conditions, showing a remarkable protective effect against H2O2-induced death in cultured rat myocytes. Moreover, 5, 2.5 and 1.25 μg/mL doses of SPEO inhibited ADP-induced rat platelet aggregation by 47.4%, 37.0%, and 32.9%, respectively [58], implying that SPEO exerted protective effects against myocardial ischemia.

Oral and intraperitoneal administration of 0.2–0.4 g of leaf extract of S. vulgaris in cats or rabbits exerted an antipyretic effect that was equal to the effect of 0.1–0.3 g of aminopyrine administered orally or intraperitoneally. However, leaf extracts of S. vulgaris are considerably more toxic than aminopyrine, with their toxic dosages being 0.4 and 1.2 g/kg, respectively [59]. In vitro evaluation of leaf extract of S. aramaticum showed its antiviral activity against herpes simplex virus at concentrations 1.25%–2.5%. The protective effect was more obvious when controlling the amount of virus attacks at 9.2–92 tissue culture infective dose (TCID50), suggesting that S. aramaticum effectively killed the virus without any harmful side effects [60-62].

Studies have reported that leaf extracts of S. aramaticum could be used for treating hemorrhoids [63]. Eugenol (112) inhibited the metabolism of arachidonic acid. Extracts of S. reticulata var. mandshurica have been used for treating bronchitis, and one of its constituents 2-(3, 4-dihydroxyphenyl) ethanol (91) significantly inhibited the production of phlegm [2].

Review and conclusions
This review describes phytochemical and pharmacological progress on the genus Syringa in the recent 20 years and discusses the future research prospects.

Syringa plants are used not only as traditional medicines to treat rheumatoid arthritis, asthma, cardiopalmus, and angina pectoris by natives in China but also for making ornaments, volatile oils, food additives, and bactericides worldwide, particularly in developing countries. Previous phytochemical studies on crude extracts from various species of this genus have identified iridoids, lignans, phenylpropanoids, and phenylethanoids having antitumor, antihypertensive, anti-oxidant, and anti-inflammatory activities. Iridoids, lignans, and phenylethanoids are the most predominant compounds in Syringa plants that probably contribute independently or synergistically to their main biological activities.

To the best of our knowledge, 46 iridoid representatives have been reported in Syringa plants, with high concentrations present in the leaves of S. vulgaris, S. pubescens, S. afghanica, S. reticulata, and S. velutina and barks of S. vulgaris and S. reticulata and low concentrations present in the flowers (S. pubescens), seeds, and seeds crust (S. oblata). This difference may be associated with their ecological roles, because iridoids are produced mainly to fight predators and/or microbes. Moreover, high concentrations of lignans in the stems and roots can be attributed to the rigidity of these plants. This may be the reason for the absence of iridoids in S. pinnatifolia var. alashanensis because materials used for chemical investigation included peeled stems and roots. Anti-inflammatory effects of extracts from these plants are mainly responsible for their applications in traditional medicine. However, only preliminary work has been performed on most isolated compounds, such as in vitro cytotoxicity screening (1, 2, 78, and 139). Limited studies have been performed on the in vivo effects of these compounds; thus, providing opportunities for further detailed research. It is particularly worthy to mention that China has an abundant resource of Syringa, with many endemic species. For instance, S. pinnatifolia var. alashanensis is a well-known Mongolian medicine traditionally used for myocardial ischemia in clinical practice. However, no substantial evidence is available on its bioactive ingredients and mechanisms of action underlying this effect. Therefore, it deserves further phytochemical and pharmacological studies.

1. Editorial Committee of Chinese Material Medica Chinese Material Medica-Mongolian volume. Shanghai Sci Technol Press. 1992;61:2–50.
2. Zhang JF, Zhang SJ. An overview of the genus Syringa: phytochemical and pharmacological aspects. Nat Sci J Hainan Univ. 2007;2:201–5.
3. Deng RX, Yuan H, Liu P, Yin WP, Wang XS, Zhao TZ. Chemical constituents from Syringa pubescens Turcz. Biochem Syst Ecol. 2010;38:813–5. doi: 10.1016/j.bse.2010.08.004. [Cross Ref]
4. Zhang GB, Liu LJ, Wang MK. Chemical constituents of volatile oils from Syringa pinnatifolia. Chin Pharm J. 1994;5:271.
5. SamyK ED, GamalEldeen AM. Cytotoxic and anti-inflammatory activities of some constituents from the floral buds of Syringa patula. Pharm Biol. 2009;47:872–7. doi: 10.1080/13880200902950785. [Cross Ref]
6. Dinda B, Debnath S, Harigaya Y. Naturally occurring iridoids. a review, part 1. Chem Pharm Bull. 2007;55:159–222. doi: 10.1248/cpb.55.159. [PubMed] [Cross Ref]
7. Ghisalberti EL. Biological and pharmacological activity of naturally occurring iridoids and secoiridoids. Phytomedicine. 1998;5:147–63. doi: 10.1016/S0944-7113(98)80012-3. [PubMed] [Cross Ref]
8. Oh H, Ko EK, Kim DH, Jang KK, Park SE, Lee HS, et al. Secoiridoid glucosides with free radical scavenging activity from the leaves of Syringa dilatata. Phytother Res. 2003;17:417–9. doi: 10.1002/ptr.1148. [PubMed] [Cross Ref]
9. Masafumi K, Yasunri Y, Nariyasu M. Glycoside from the leaves of Syringa vulgaris and their growth inhibitory activity against human cancer cell lines. Japan Soc Pharm. 2010;64:104–5.
10. Bi XY, Li W, Sasaki T, Li Q, Mitsuhata N, Asada Y, et al. Secoiridoid glucosides and related compounds from Syringa reticulata and their anti-oxidant activities. Bioorg Med Chem Lett. 2011;21:6426–9. doi: 10.1016/j.bmcl.2011.08.089. [PubMed] [Cross Ref]
11. Kikuchi M, Yaoita Y, Mano N, Kikuchi M. Structure and cytotoxic activity of enzymatic hydrolysis products of secoiridoid glucosides, isoligustroside and isooleuropein. Chem Biodivers. 2011;8:651–7. doi: 10.1002/cbdv.201000092. [PubMed] [Cross Ref]
12. Park HJ, Lee MS, Lee KT, Sohn IC, Han YN, Miyamoto K. Studies on constituents with cytotoxic activity from the stem bark of Syringa velutina. Chem Pharm Bull. 1999;47:1029–31. doi: 10.1248/cpb.47.1029. [PubMed] [Cross Ref]
13. Yk T, Okazaki N, Tanahashi T, Nagakura N, Nishi T. Secoiridoid and iridoid glucosides from Syringa afghanica. Phytochemistry. 2002;59:779–87. doi: 10.1016/S0031-9422(02)00024-9. [PubMed] [Cross Ref]
14. Nenadis N, Vervoort J, Boeren S, Tsimidou MZ. Syringa oblata Lindl var. alba as a source of oleuropein and related compounds. J Sci Food Agr. 2007;87:160–6. doi: 10.1002/jsfa.2697. [Cross Ref]
15. Kikuch IM, Yamauchi Y, Yanase C. Structures of new secoiridoid glycosides from the leaves of Syringa vulgaris Linn. Yakugakuzasshi. 1987;107:245–8.
16. Machida K, Kaneko A, Hosogai T, Kakuda R, Yaoita Y, Kikuchi M. Studies on the constituents of Syringa species. X. five new iridoid glycosides from the leaves of Syringa reticulata (Blume) Hara. Chem Pharm Bull. 2002;50:493–7. doi: 10.1248/cpb.50.493. [PubMed] [Cross Ref]
17. Sticher O, Ahmad M, Salama O, Winkler T. Two new secoiridoid glucosides from Syringa vulgaris. Planta Med. 1982;45:151. doi: 10.1055/s-2007-971324. [PubMed] [Cross Ref]
18. Kikuch IM, Yamauchi Y, Takahashi Y. Structures of new secoiridoid glycosides from the leaves of Syringa vulgaris Linn. Yakugakuzasshi. 1988;108:355–60.
19. Machida K, Unagami E, Ojima H, Kikuchi M. Studies on the constituents of Syringa species. XII. new glycosides from the leaves of Syringa reticulata (Blume) Hara. Chem Pharm Bull. 2003;51:883–4. doi: 10.1248/cpb.51.883. [PubMed] [Cross Ref]
20. Garcia J, Lavaitte S, Gey C. 8-Epikingiside and its vanillate ester, isolated from Gentiana pyrenaica. Phytochemistry. 1989;28:2199–201. doi: 10.1016/S0031-9422(00)97944-5. [Cross Ref]
21. Feng XS, Qu Y, Wu ZHXL, Zhang DS, Gao HY, Wu LJ. Two new secoiridoid glucosides from Syringa velutina Kom. Chinese Chem Lett. 2009;20:702–5. doi: 10.1016/j.cclet.2009.02.012. [Cross Ref]
22. Asaka Y, Kamikawa T, Tokoroyama T, Kubota T. The structure and absolute configuration of syringopicroside. a new iridoid glucoside from Syringa vulgaris. Tetrahedron. 1970;26:2365–70. doi: 10.1016/S0040-4020(01)92815-7. [PubMed] [Cross Ref]
23. Zhou YM, Gao HY, Wu B, Li SH, Wu LJ. Structure determination of syringopicroside from the leaves of Syringa oblata Lindl. using 2D NMR spectral methods. Asian J Tradit Med. 2006;1:31–3.
24. Zhang SJ, Guo HQ, Han J, Zhao M, Wang JJ. Chemical constituents from seeds of Syringa oblata. Chin Tradit Herbal Drugs. 2011;42:1894–900.
25. Wang JL, Zhang GF, Dong LW, Zhao M, Zhang SJ. Chemical constituents from seed crust of Syringa oblata. Chin Tradit Herbal Drugs. 2010;41:1598–601.
26. Kikuch IM, Yamauchi Y, Takahashi Y. Studies on constituents of Syringa species. VIII. Isolation and structures of phenylpropanoid glycosides from the leaves of Syringa reticulata (Blume) Hara. Yakugakuzasshi. 1989;109:366–71.
27. Luo Y, Liu Y, Qi H, Wu Z, Zhang G. Steryl esters and phenylethanol esters from Syringa komarowii. Steroids. 2006;71:700–5. doi: 10.1016/j.steroids.2006.04.004. [PubMed] [Cross Ref]
28. Feng XS, Qu Y, Xu L, Wang DC, Wu LJ, Meng FH, et al. Two new neolignans from Syringa velutina Kom. Molecules. 2009;14:953–8. doi: 10.3390/molecules14030953. [PubMed] [Cross Ref]
29. Kurkin VA. Phenylpropanoids from medicinal plants: distribution, classification, structural analysis, and biological activity. Chem Nat Compd. 2003;39:123–53. doi: 10.1023/A:1024876810579. [Cross Ref]
30. Zeng XJ, Wang GC, Wu X, Li YL. Chemical constituents from Syringa pinnatifolia. Chin Tradit Herbal Drugs. 2013;7:1721–5.
31. Ao WLJ, Bao XH, Wu XL, Wang QH. Lignans from Syringa pinnatifolia var. alashanensis. J Asian Nat Prod Res. 2012;14:396–400. doi: 10.1080/10286020.2012.656606. [PubMed] [Cross Ref]
32. Xu QM, Li Q, Liu YL, Feng YL, Yang SL, Li XR. New lignans from Syringa reticulata var. mandshurica. Chem Nat Compd. 2010;46:366–9. doi: 10.1007/s10600-010-9618-1. [Cross Ref]
33. Wang QH, Ao WLJ, Wu QS, Ying X. Two new neolignans from the stems of Syringa pinnatifolia var. alashanensis. Helv Chim Acta. 2012;95:1680–5. doi: 10.1002/hlca.201200118. [Cross Ref]
34. Ao WLJ, Wang QH, Wang XL, Dai YNT. Extraction and structure elucidation of three lignans from peeled dried roots and stems of Syringa pinnatifolia. Chin Tradit Herbal Drugs. 2013;7:791–3.
35. Machida K, Ohkawa N, Ohsawa A, Kikuchi M. Two new phenolic glycosides from Syringa reticulata. J Nat Med. 2009;63:192–4. doi: 10.1007/s11418-008-0295-3. [PubMed] [Cross Ref]
36. Ahmad M, Rizwan GH, Aftab K, Ahmad VU, Gilani AH, Ahmad SP. Acteoside: a new antihypertensive drug. Phytother Res. 1995;9:525–7. doi: 10.1002/ptr.2650090713. [Cross Ref]
37. Ao WLJ, Wang QH, Si Q, Mu D, Sa RTY, Dai NYT, et al. The structural elucidation and antimicrobial activities of two new sesquiterpenes from Syringa pinnatifolia. Chin J Nat Med. 2012;10:477–80.
38. Li ZG, Lee MR, Shen DL. Analysis of volatile compounds emitted from fresh Syringa oblata flowers in different florescence by headspace solid-phase microextraction-gas chromatography–mass spectrometry. Anal Chim Acta. 2006;1:43–9. doi: 10.1016/j.aca.2006.01.074. [PubMed] [Cross Ref]
39. Chen XZ, Liang YZ, Fang HZ, Li XN. Temperature-programmed retention indices for gas chromatography-mass spectroscopy analysis of plant essential oils. J Chromatogr A. 2005;1096:76–85. doi: 10.1016/j.chroma.2005.09.067. [PubMed] [Cross Ref]
40. Yu AN, Yang XZ. Chemical composition of the essential oil of fresh wild Syringa pubescens flowers from China. Adv MaterRes (Durnten-Zurich, Switzerland) 2012;22:581–2.
41. Kikuch IM, Yamauchi Y. Studies the constituents of Syringa species. I. Isolation and structures of iridiods and secoiridoids from the leaves of Syringa reticulata (Blume) Hara. Yakugakuzasshi. 1987;107:350–4.
42. Ahmad M, Salama O, Sticher O. Isolation of echinacoside from the white flowers of Syringa vulgaris. J Chem Soc Pakistan. 1987;9:451–4.
43. Xu QM, Liu YL, Li XR, Feng YL, Yang SL. Two new phenylglycol derivatives isolated from Syringa reticulata var. mandshurica and their antifungal activities. Chem Pharm Bull. 2009;57:863–6. doi: 10.1248/cpb.57.863. [PubMed] [Cross Ref]
44. Ao WLJ, Wang QH, Dai YNT. Chemical detection on the stems of Syringa pinnatifolia var. alashanensis. Chin Hosp Pharm J. 2013;33:1544–6.
45. Kurkin VA. Phenylpropanoids as the biologically active compounds of the medicinal plants and phytopharmaceuticals. Adv Biol Chem. 2013;3:26–8. doi: 10.4236/abc.2013.31004. [Cross Ref]
46. Ahmad M, Aftab K. Hypotensive action of syringin from Syringa vulgaris. Phytother Res. 1995;9:452–4. doi: 10.1002/ptr.2650090614. [Cross Ref]
47. Kikuch IM, Yamauchi Y. Studies on constituents of Syringa species I. Isolation and structure of iridodids and secoiridoids from the leaves of Syringa reticulata (Blume) Hara. Yakugakuzasshi. 1987;107:23–7.
48. Kurkin VA, Zapesochnaya GG, Ginenko NA, Zolotarev BM. Phenolic compounds from the bark of Syringa vulgaris. Chem Nat Compd. 1989;4:581–3.
49. Ahmad M, Salama O. Flavonoids from violet flowers of Syringa vulgaris. Pakistan J Sci Ind Res. 1987;30:150–1.
50. Ahmad M, Salama O. Isolation of rutin from the fresh leaves of Syringa vulgaris. J Pharm. 1985;4:9–11.
51. Yin WP, Zhao TZ, Zhang HY. A novel oligosaccharide ester from Syringa pubescens. J Asian Nat Prod Res. 2008;10:95–100. doi: 10.1080/10286020701394241. [PubMed] [Cross Ref]
52. Helmut R. Jasminidin, ein neues monoterpenalklaloid aus Syringa vulgaris. Phytochemistry. 1978;17:1069–70. doi: 10.1016/S0031-9422(00)94288-2. [Cross Ref]
53. Liu X, Wang JM. Iridoid glycosides fraction of Folium Syringae leaves modulate NF-κB signal pathyway and intestinal epithelial cells apoptosis in experimental colitis. Plos One. 2011;6:e24740. doi: 10.1371/journal.pone.0024740. [PMC free article] [PubMed] [Cross Ref]
54. Liu X, Wang JM. Anti-inflammatory effects of iridoid glycosides fraction of Folium Syringae leaves on TNBS-induced colitis in rats. J Ethnopharmacol. 2011;133:780–7. doi: 10.1016/j.jep.2010.11.010. [PubMed] [Cross Ref]
55. Gao SQ, Niu JQ, Wang F, Wang F, Liu XD, Jin ZX, et al. Comparative studies on the resistance of hepatitis B by Syringa extract, IFN and ganyanling in HepG2.2.15 cells. Chin J Cell Mol Immunol. 2003;19:385–6. [PubMed]
56. Yao DL, Han ZG, Zhou W, Ju GM, Li G. Protective effects of the Syringa reticulata var. mandshurica extract against acute liver injury in mice. J Med Sci Yan B Univ. 2009;32:29–31.
57. Li JX. The Syringa aramaticum modern pharmacological research. P J Pract Tradit Chin Med. 2002;18:54.
58. Yan Y, WLJ O, Zhao XJ, Ye XC, Zhang C, Hao JJ, et al. Effect of essential oil of Syringa pinnatifolia var. alashanensis on ischemia of myocardium, hypoxia and platelet aggregation. J Ethnopharmacol. 2010;131:248–55. doi: 10.1016/j.jep.2010.06.027. [PubMed] [Cross Ref]
59. Balint G, Eperjessy ET, Thuranszky K. Hypothermic action of the leaf extract of Syringa vulgaris. Acta Physiolo Acad Sci Hung. 1965;28:399–406. [PubMed]
60. Yang WW, Xing MY. The preparations of Syringa oblata leaves change in immunoassay after the treatment on herpes simplex keratitis. Chin J Pract Ophthalmolol. 1990;8:252–61.
61. Xing MY. The preparations of Syringa oblata leaves change in tears’ PH after the treatment on herps simplex keratitis. Chin J Ophthalmolol. 1992;10:312–21.
62. Xing MY, Li B. The preparations of Syringa oblata leaves treat epidemic hermorrhagic conjunctivitis. Chin J Ophthalmolol. 1996;14:301.
63. Li SJ, Xu LY. The preparations of Syringa oblata leaves treat hemorrhoids with 18 cases. China Acad J. 2001;1:57.